|Calculated MW||This protein contains C-terminal polyhistidine tag and has a calculated MW of 57.8 kDa. As a result of glycosylation, DTT-reduced protein migrates as 65 - 70 kDa polypeptide in SDS-PAGE.|
|Other Names||EphB4, HTK, MYK1, TYRO11, Ephrin-type-B-receptor-4.|
|Results||Measured by its binding ability in a functional ELISA. Immobilized rhEPHB4 at 2 µg/ml (100 µl/well) can bind human EphrinB2 with a linear range of 0.8 - 85 ng/ml.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Ephrin type-B receptor 4 (EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. In contrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.
Bennett B.D.,et al.J. Biol. Chem. 269:14211-14218(1994).
Wilson M.D.,et al.Nucleic Acids Res. 29:1352-1365(2001).
Jin P.,et al.Arthritis Res. Ther. 10:R73-R73(2008).
Fueller T.,et al.J. Cell Sci. 116:2461-2470(2003).
Erber R.,et al.EMBO J. 25:628-641(2006).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.